News

05/17/2018

Obsidian Presents Preclinical Data at ASGCT Showing Advancement of its Regulated IL12 and IL15 Programs to Enable Safer and More Effective CAR-T Therapies

MORE >

05/01/2018

Obsidian to Present Data on Regulated Cytokine Programs at the Upcoming American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting

MORE >

04/17/2018

Obsidian Therapeutics Presents Preclinical Data from Regulated Cytokine Programs that Enable CAR-T Therapies with Controllable Functions

MORE >

03/19/2018

Obsidian Therapeutics to Present at Upcoming Investor Conferences

MORE >

03/15/2018

Obsidian to Present Data on its Destabilizing Domain Technology and Product Programs at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting

MORE >

02/13/2018

Obsidian Therapeutics to Present Data Demonstrating Regulation of Protein Activity with its Next-Generation CAR-T Platform at Keystone Symposium on Emerging Cellular Therapies

MORE >

12/06/2017

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

MORE >

We would like to collect information during your visit to help us better understand site use. This data is anonymized, and will not be used for marketing purposes. Read More on our Privacy Policy page. You can withdraw permission at any time or update your privacy settings here. Please choose below to continue.

Yes, I agree No, Please do not